Follow us...


Search News Archives

Monthly Newsletter

Lab Bulletin January Newsletter




News Channels


New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature


Events | Webinars



Conferences | Events
Cellular Dynamics International

Cellular Dynamics International

Cellular Dynamics International


Contact Cellular Dynamics International

If you have not logged into the website then please enter your details below.

All articles from Cellular Dynamics International

  iPS Academia Japan, Inc. to Distribute Cellular Dynamics' iCell Products in Japan Cellular DynamicsCellular Dynamics International, Inc. (CDI) today announced an agreement with iPS Academia Japan, Inc., who will distribute CDI's iCell® Cardiomyocytes, the first commercially available product based on induced pluripotent stem cells (iPSCs), in Japan. This distribution agreement brings the vision of the two pioneers of iPSC technology, Dr. James Thomson and Dr. Shinya Yamanaka, a step closer to making the technology widely available to researchers worldwide and thus impacting human health and biological research...


  Cellular Dynamics International Scientists Report on Efficient Method to Produce Footprint-Free Induced Pluripotent Stem Cells (iPSCs) Under Feeder-free Conditions Cellular Dynamics InternationalCellular Dynamics International (CDI), the world's largest producer of human tissue cells for drug discovery and safety testing, today announced the publication of research demonstrating an efficient and scalable method of creating DNA integration-free, or footprint-free, induced pluripotent stem cells (iPSCs) under a feeder-free condition using chemically defined media...


  Cellular Dynamics International, ACEA Biosciences, and Roche Applied Sciences Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System Cellular Dynamics International LogoCellular Dynamics International (CDI) announced their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process. The partnership combines CDI's induced pluripotent stem cell (iPSC)-derived heart cells, iCellTM Cardiomyocytes, with the xCELLigenceTM RTCA System. The xCELLigence System is developed by ACEA and Roche Applied Science and marketed by Roche




Media Partners